Next Article in Journal
Pharmacokinetics and Anti-Gastric Ulceration Activity of Oral Administration of Aceclofenac and Esomeprazole in Rats
Previous Article in Journal
Thermo-Sensitive Vesicles in Controlled Drug Delivery for Chemotherapy
Article Menu

Export Article

Open AccessArticle
Pharmaceutics 2018, 10(3), 151; https://doi.org/10.3390/pharmaceutics10030151

Development of Dual Drug Loaded Nanosized Liposomal Formulation by A Reengineered Ethanolic Injection Method and Its Pre-Clinical Pharmacokinetic Studies

1
School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan 430030, Hubei, China
2
International Joint Laboratory of Nuclear Protein, Henan University, Kaifeng 475001/475004, Henan, China
3
Faculty of Pharmacy, The University of Lahore (UOL), Lahore 56400, Punjab, Pakistan
4
Institute of Pharmacy, Lahore College for Women University (LCWU), Lahore 54610, Punjab, Pakistan
These authors contributed equally to this work.
*
Authors to whom correspondence should be addressed.
Received: 4 July 2018 / Revised: 29 August 2018 / Accepted: 31 August 2018 / Published: 6 September 2018
Full-Text   |   PDF [21305 KB, uploaded 6 September 2018]   |  

Abstract

Oleanolic acid (OA), which is a natural pentacyclic terpenoid, has been identified for hepato-protective, nephron-protective and cardio-tonic properties. In contrast, doxorubicin (DOX) is a famous anti-cancer drug but its efficacy is a question mark because of its known cardio-toxicity. We developed a combined nanoliposomal formulation of DOX with OA, as adjuvant, to overwhelm toxic effects of DOX without compromising anticancer activity. The entrapment efficiency and the particle size were brought in limit by the reengineered ethanolic injection method (REIM), without further extrusion. The developed formulations were stable over the study period of two months. A modified HPLC method was employed for the analysis of OA (drug retention time, Tr = 12 ± 1 min). The recovery of OA against spiked plasma samples was more than 90%. MTT assay showed anti-apoptotic synergism against HepG2 cells at non-fixed ratio (combination index, CI < 1). A sustained in vivo drug release of experimental drugs was depicted over 24 h. Histopathological examination and laboratory findings indicated no visible sign of toxicity in the treated mice group against combined delivery. Hence, this combined nanoliposomal formulation was tagged as a safer therapy for the DOX based cancer treatments. View Full-Text
Keywords: oleanolic acid; doxorubicin; pegylated liposomes; reengineered ethanolic injection method; cardiotoxicity oleanolic acid; doxorubicin; pegylated liposomes; reengineered ethanolic injection method; cardiotoxicity
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Sarfraz, M.; Afzal, A.; Yang, T.; Gai, Y.; Raza, S.M.; Khan, M.W.; Cheng, Y.; Ma, X.; Xiang, G. Development of Dual Drug Loaded Nanosized Liposomal Formulation by A Reengineered Ethanolic Injection Method and Its Pre-Clinical Pharmacokinetic Studies. Pharmaceutics 2018, 10, 151.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top